{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T08:07:18Z","timestamp":1770797238532,"version":"3.50.0"},"reference-count":43,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2005,8,15]],"date-time":"2005-08-15T00:00:00Z","timestamp":1124064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2005,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The authors evaluated the efficacy of chemotherapy combined with rituximab followed by high\u2010dose therapy (HDT) plus autologous stem cell transplantation in patients with mantle cell lymphoma (MCL).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>This was a retrospective analysis of 34 patients who were treated in 2 departments of hematology, including 29 patients (85%) who received first\u2010line treatment. Rituximab was administered as 4 injections just before harvest in 25 patients (73%) or simultaneously with chemotherapy in 9 patients (27%). HDT included total body irradiation in 26 patients (77%).<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>After induction therapy, all patients except one reached a response: There were 14 (41%) complete responses (CR) and 19 (56%) partial responses (PR). Stem cell harvest was successful in all patients but 2, with a median number of 5.9 CD34\u2010positive cells per 10<jats:sup>6<\/jats:sup>\/kg. Three months after transplantation, 24 patients (71%) were in CR, and 7 patients (21%) were in PR. At 3 years from the day of transplantation, the estimated overall survival was 87%. With a median follow\u2010up at 2.6 years, the estimated median time to disease progression was 3.4 years. Rituximab treatment before harvest did not delay hematopoietic reconstitution: The median time it took patients to recover absolute neutrophil count to &gt; 0.5 G\/L was 10 days.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Chemotherapy combined with rituximab followed by HDT improved the overall survival and progression\u2010free survival in patients MCL without adding toxicities. Cancer 2005. \u00a9 2005 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.21313","type":"journal-article","created":{"date-parts":[[2005,8,15]],"date-time":"2005-08-15T15:50:16Z","timestamp":1124121016000},"page":"1434-1441","source":"Crossref","is-referenced-by-count":32,"title":["Chemotherapy with rituximab followed by high\u2010dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma"],"prefix":"10.1002","volume":"104","author":[{"given":"Catherine","family":"Thieblemont","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daciana","family":"Antal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Lacotte\u2010Thierry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Delwail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Espinouse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne\u2010Sophie","family":"Michallet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Traulle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadhela","family":"Bouafia\u2010Sauvy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Giraud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Guilhot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Coiffier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,9,17]]},"reference":[{"key":"e_1_2_5_2_2","volume-title":"World Health organization classification of tumours. Tumours of haematopoietic and lymphoid tissues","author":"Jaffe E","year":"2001"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.6610211"},{"key":"e_1_2_5_4_2","first-page":"115","article-title":"Mantle\u2010cell lymphoma","volume":"36","author":"Campo E","year":"1999","journal-title":"Semin Hematol."},{"key":"e_1_2_5_5_2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/oxfordjournals.annonc.a059148","article-title":"Mantle cell lymphoma: a therapeutic dilemma","volume":"6","author":"Coiffier B","year":"1995","journal-title":"Ann Oncol."},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.5.1922"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401121"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.11.2819"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402406"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.2.546"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.579"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(02)00143-0"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.4.1262"},{"key":"e_1_2_5_14_2","first-page":"1975","article-title":"Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma","volume":"10","author":"Haas R","year":"1996","journal-title":"Leukemia."},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701046"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008278605751"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3803"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a059156"},{"key":"e_1_2_5_19_2","first-page":"3572","article-title":"Myeloablative radiochemotherapy followed by autologous blood stem cell transplantation leads to a significant prolongation of event\u2010free survival in patients with mantle cell lymphoma (MCL)\u2014results of a prospective randomized European intergroup study","volume":"98","author":"Hiddemann W","year":"2001","journal-title":"Blood."},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.13"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.10.4212"},{"key":"e_1_2_5_22_2","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1182\/blood.V89.2.724","article-title":"Molecular monitoring of minimal residual disease in follicular and mantle cell non\u2010Hodgkin's lymphomas treated with high\u2010dose chemotherapy and peripheral blood progenitor cell autografting","volume":"89","author":"Corradini P","year":"1997","journal-title":"Blood."},{"key":"e_1_2_5_23_2","first-page":"1927","article-title":"Rituximab (anti\u2010CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter Phase II study","volume":"15","author":"Coiffier B","year":"1998","journal-title":"Blood."},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008309405678"},{"key":"e_1_2_5_25_2","volume-title":"Blood","author":"Howard O","year":"1999"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1323"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.3.864"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I"},{"key":"e_1_2_5_29_2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/oxfordjournals.annonc.a059149","article-title":"Fourteen years of high\u2010dose CHOP (ACVB regimen): preliminary conclusions about the treatment of aggressive\u2010lymphoma patients","volume":"6","author":"Coiffier B","year":"1995","journal-title":"Ann Oncol."},{"key":"e_1_2_5_30_2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1182\/blood.V71.1.117.117","article-title":"Effective salvage therapy for lymphoma with cisplatin in combination with high\u2010dose Ara\u2010C and dexamethasone (DHAP)","volume":"71","author":"Velasquez W","year":"1998","journal-title":"Blood."},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.6.1169"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200007"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.5.1288"},{"key":"e_1_2_5_37_2","doi-asserted-by":"crossref","first-page":"40a","DOI":"10.1182\/blood.V104.11.128.128","article-title":"Rituximab plus hypercvad (R\u2010HCVAD) alternating with rituximab plus high\u2010dose methotrexate\u2010cytarabine (R\u2010M\/A) in untreated mantle cell lymphoma (MCL): prolonged follow\u2010up confirms high rates of failure\u2010free survival (FFS) and overall survival (OS)","volume":"104","author":"Romaguera J","year":"2004","journal-title":"Blood."},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703925"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2476"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh069"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh425"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.9.3148"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200306263482620"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.21313","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.21313","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T12:34:25Z","timestamp":1760272465000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.21313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,17]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["10.1002\/cncr.21313"],"URL":"https:\/\/doi.org\/10.1002\/cncr.21313","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9,17]]}}}